{"id":"W4289912960","doi":"10.1007/s40744-022-00474-5","title":"Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"AbbVie; Boehringer Ingelheim","keywords":"Medicine; Placebo; Internal medicine; Rheumatology; Psoriatic arthritis; Randomized controlled trial; Adverse effect; Clinical endpoint; Psoriasis Area and Severity Index; Psoriasis; Gastroenterology; Arthritis; Physical therapy; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001978913,0.0001764495,0.00111323,0.000098694,0.0001604482,0.000004837628,0.00003814165,0.00006103023,0.0001047627],"category_scores_gemma":[0.0000966498,0.0001315154,0.00005865968,0.0001085621,0.0002470768,0.00004176419,0.00004072162,0.0001724783,6.600493e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000026126,"about_ca_system_score_gemma":0.00004533005,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002773283,"about_ca_topic_score_gemma":0.00005133026,"domain_scores_codex":[0.9985334,0.0003045722,0.000490571,0.0003216503,0.0001629412,0.0001868566],"domain_scores_gemma":[0.9988027,0.0007005464,0.000239735,0.0001685737,0.00003159841,0.00005690346],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8500456,0.002885247,0.02201118,0.000007602017,0.0008228141,0.0000619481,0.002147773,3.94444e-7,0.000001260892,0.00006313503,0.000007662782,0.1219454],"study_design_scores_gemma":[0.8772438,0.005787279,0.1162608,0.0001499695,0.00007501808,0.0000299451,0.0001352822,0.000005306343,0.00002101624,0.0001572068,0.00003454557,0.00009993772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893534,0.007978597,0.000004719109,0.0001374382,0.0001677681,0.002038509,0.0002450518,0.00001516445,0.00005937784],"genre_scores_gemma":[0.9878656,0.01156155,0.00004655448,0.00004140711,0.000008794968,0.0001817801,0.000271588,0.0000141201,0.000008622364],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1218454,"threshold_uncertainty_score":0.5363042,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01031434900425969,"score_gpt":0.2628086861174515,"score_spread":0.2524943371131918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}